Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trimeris, a developer of antiviral drug treatments called fusion inhibitors, has reported total revenue of $3.45m for the second quarter ended 30 June 2011, compared to $3.26m for the same period in 2010.
Subscribe to our email newsletter
The company has posted a net income of $673,000 for the second quarter of 2011, compared to $1.35m for the same period in 2010.
The company’s operating income was $813,000 compared to $2.13m for the same period prior year.
For the six months ended 30 June 2011, the company’s total revenue was $5.05m, compared to $6.39m for the same period in 2010.
Trimeris has reported net income of $606,000 for the six months ended 30 June 2011, compared to $2.33m for the same period in 2010.
For the six months ended 30 June 2011, the company’s operating income was $701,000, compared to $3.83m for the same period prior year.
The overall decline in net income for the quarter and six months resulted primarily from decreased worldwide net sales of Fuzeon and increased general and administrative fees related to the Trimeris process to evaluate and identify a strategic partner as well as Trimeris’ proposed merger with Synageva BioPharma.